F. Boisnard

发表

Antibody persistence against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) in 5-6-year-old children after primary vaccination and first booster with a pentavalent combined acellular pertussis vaccine: immunogenicity and tolerance of a tetravalent combined acel

E. Mallet, N. Matisse, Nicolas Mathieu, 2004, Vaccine.

A Phase III Randomized, Double-blind, Clinical Trial of an Investigational Hexavalent Vaccine Given at Two, Three, Four and Twelve Months

T. Vesikari, F. Boisnard, T. Becker, 2017, The Pediatric infectious disease journal.

A Phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11-12 months.

G. Icardi, T. Vesikari, F. Boisnard, 2016, Vaccine.

Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib).

F. Martinón-Torres, F. Boisnard, R. Borrow, 2017, Vaccine.

Concomitant administration of a fully liquid ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal ACWY conjugate vaccine in toddlers.

S. Lockhart, T. Vesikari, F. Boisnard, 2018, Vaccine.

Vaccination in pregnancy against pertussis and seasonal influenza: key learnings and components from high-performing vaccine programmes in three countries: the United Kingdom, the United States and Spain

Litjen Tan, C. Jones, F. Boisnard, 2021, BMC Public Health.

Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine.

N. Kitchin, F. Boisnard, E. Miller, 2009, Vaccine.

Vaccination in pregnancy against pertussis and seasonal influenza: key learnings and components from high-performing vaccine programmes in three countries: the United Kingdom, the United States and Spain

C. Jones, F. Boisnard, Marta García Sánchez, 2021, BMC Public Health.

Immunogenicity and Reactogenicity of a Combined Adsorbed Tetanus Toxoid, Low Dose Diphtheria Toxoid, Five Component Acellular Pertussis and Inactivated Polio Vaccine in Six-Year-Old Children

F. Boisnard, J. Díez-Domingo, A. Ballester, 2005, The Pediatric infectious disease journal.

DTaP5-IPV-Hib-HepB, a hexavalent vaccine for infants and toddlers

F. Boisnard, E. Jordanov, G. Marshall, 2017, Expert review of vaccines.

Interchangeability of Hepatitis A boosters, Avaxim and Vaqta, in healthy adults following a primary dose of the combined typhoid/Hepatitis A vaccine Viatim.

M. Watson, F. Boisnard, S. Thomas, 2006, Vaccine.

Immunogenicity of a liquid hexavalent DTaP-IPV-HB-PRP∼T vaccine after primary and booster vaccination of term and preterm infants born to women vaccinated with Tdap during pregnancy.

F. Boisnard, O. Lyabis, K. Maertens, 2022, Vaccine.

[Central nervous system demyelinating disease following hepatitis B vaccination with GenHevac B. Review of ten years of spontaneous notifications (1989-1998)].

F. Boisnard, B. Soubeyrand, M. Bruel, 2000, Presse medicale.

Safety and immunogenicity of fully liquid DTaP₅-IPV-Hib pediatric combination vaccine (Pediacel®) compared to DTaP₃-HBV-IPV/Hib (Infanrix® Hexa) when coadministered with heptavalent pneumococcal conjugate vaccine (PCV7) as a booster at 11-18 months of age: a phase III, modified double-blind, randomi

F. Boisnard, R. Berner, G. Mwawasi, 2012, Vaccine.

Immunogenicity and safety of fully liquid DTaP₅-IPV-Hib compared with DTaP₃-IPV/Hib when both coadministered with a heptavalent pneumococcal conjugate vaccine (PCV7) at 2, 3, 4, and 12 to 18 months of age: a phase III, single-blind, randomised, controlled, multicentre study.

F. Boisnard, E. Grimprel, J. Wysocki, 2011, Vaccine.